You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Nanoimmunotherapy for chronic immune-mediated diseases
SBC: GENERAL NANOTHERAPEUTICS LLC Topic: NIAIDABSTRACT Current pharmaceutical agents that are used for the treatment of immune-mediated inflammatory conditions including autoimmune diseases generally do not lead to remission and frequently carry toxic side effects. Here we propose a strategy that can harness the capacity of the immune system to induce immunoregulatory response that can suppress immune hyperactivity and chronic inflammation in ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A web-based platform to support team-based genome diagnostics
SBC: FRAMESHIFT LABS INC Topic: 172Summary/Abstract Genomic sequencing is rapidly becoming a standard tool in diagnosing complex diagnostic cases, especially in critically ill newborns, and patients suffering from rare diseases. Current programs focused on addressing these cases utilise a team-based approach to identify, interpret and evaluate a patient’s genetic variants. These diverse teams include bioinformaticians, medical ge ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Brillouin optical eye scanner prototypes for commercialization
SBC: Intelon Optics, Inc. Topic: 100ABSTRACT The overall goal of this STTR project is to commercialize a novel optical eye scanner device capable of measuring the biomechanical properties of tissues via Brillouin light scattering. The Brillouin technology invented in the co-PI’s lab has shown broad potential for improving the diagnosis and treatment of vision disorders. Clinical data obtained with current laboratory systems reveal ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Thermostable Inactivated Potent Yellow Fever Vaccine
SBC: UNIVERSAL STABILIZATION TECHNOLOGIES, INC. Topic: NIAIDSummaryYellow Fever (YF) is an acute viral hemorrhagic fever disease caused by Yellow Fevervirus (YFV) and an estimated 200,000 YF infections occur annually. Approximately 50% ofinfected individuals that develop a severe case of the disease will die. The infection iscommon in Africa and South America, and travelers and residents of those areas are athigh risk of contracting the virus. A recent res ...
STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health -
High Density Cell Respirator (HDCR) for the production of vectors, viruses and vaccines
SBC: XDemics Corporation Topic: 100PROJECT SUMMARY/ABSTRACT This Phase I/II STTR Fast Track proposal responds to the call from the 2018/2019 NCATS SBIR/STTR Research Priorities to develop technologies so that “new treatments and cures for disease can be delivered to patients more quickly”. The production of life-altering gene editing vectors, cancer killing viruses, and life- saving vaccines currently depends on traditional cel ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
A digital tool for monitoring speech decline in ALS
SBC: MODALITY.AI , INC Topic: NIDCDPROJECT SUMMARYAmyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease resulting in the progressive loss of limb, trunk, and head and neck (bulbar) motor function and is the most common adult-onset motor neuron disease. The disease is characterized by significant across-patient heterogeneity in the onset region and in pattern and progression rate, making early and accurate diagnos ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials
SBC: MOUNTAINPASS TECHNOLOGY LLC Topic: NCATSABSTRACT Remote trials are led and coordinated by a local investigative team, but are based remotely, typically in the participant’s home. Remote trials offer several advantages over traditional in-person trials including: 1) a wider participant pool, 2) reduced regulatory hurdles, and 3) reduced participant burden. Remote trials face one key methodological limitation: the need for biomarker col ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
SBC: Aromha Inc Topic: NIAProject Summary / Abstract Over 5.8 million Americans are currently affected by Alzheimerandapos;s disease (AD) with an economic burden estimated at andgt; $270 billion/year in 2020 that is projected to increase at least four fold over the next several decades. Accurate biomarkers have been developed that demonstrate that AD pathology is present 15 years of more prior to the onset of memory sympto ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health -
Computer-based Learning to Enhance ADRD Care in Prison: Just Care for Dementia
SBC: KLEIN BUENDEL, INC. Topic: RProject Summary/Abstract U.S. prison systems face sharply increased demands in caring for older people living in prisons. Alzheimerandapos;s Disease and related dementias (ADRD) are age-related diseases. Prison populations are over- represented by minority populations who experience disparities in prevalence and incidence of dementia. Prison health, social, and security staff perceive they lack th ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development and evaluation of diffuse correlation spectroscopy to monitor cerebral blood flow and detect intraventricular hemorrhage in extremely premature infants
SBC: 149 MEDICAL INC Topic: 103PROJECT SUMMARY/ABSTRACT Every year in the United States about 30% of the 60,000 infants born extremely premature (andlt;30 weeks gestational age and andlt;1000 g birth-weight [ELGA]) develop intraventricular hemorrhage (IVH). IVH is associated with high risk for cerebral palsy and significant intellectual disability, causing lifelong implications for affected children and their families and consi ...
STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health